威高集团：从威海走向世界的医疗器械领军者
Weigao Group:A Leading Medical Device Pioneer Rising from Weihai to the World
2025年11月25日下午多家海外华文媒体走进中国威海的杰出企业——威高集团。这家企业不仅是中国医疗器械行业的骄傲，更是全球医疗领域的重要参与者，它的故事值得我们共同关注。
On the afternoon of November25,2025,several overseas Chinese media outlets visited Weigao Group,a remarkable enterprise based in Weihai,China.The company is not only a source of national pride in China’s medical device industry but also an important global player in the medical field.Its story deserves our full attention.
一、创业初心与发展历程
I.Founding Vision and Development Journey
威高集团成立于1988年，创始人陈学利从生产一次性输液器起步，初衷是改善孤寡老人的生活。当时，中国医疗耗材依赖进口，价格高昂，基层医院难以承受。威高凭借高性价比和可靠质量，迅速占领国内市场，成为一次性医疗耗材领域的“王者”。
Founded in1988,Weigao Group began with the production of disposable infusion sets.Its founder,Chen Xueli,was driven by a desire to improve the lives of solitary elderly people.At that time,China relied heavily on imported medical consumables,which were expensive and unaffordable for grassroots hospitals.Thanks to its competitive pricing and reliable quality,Weigao quickly captured the domestic market and became the dominant player in disposable medical supplies.
2004年，威高在香港联交所主板上市，募集资金加速产业升级。如今，威高已发展为拥有13个产业集团、100多家子公司，其中3家上市公司、8家海外公司的现代化企业集团，业务覆盖医疗器械和医药领域，员工达3万多人。
In2004,Weigao was listed on the Main Board of the Hong Kong Stock Exchange,raising capital that accelerated its industrial upgrading.Today,the company has grown into a modern enterprise group with13industrial divisions and more than100subsidiaries,including3listed companies and8overseas branches.Its businesses span medical devices and pharmaceuticals,employing more than30,000people.
二、核心业务与行业地位
II.Core Businesses and Industry Position
威高集团的业务涵盖医疗耗材、医疗设备、骨科医疗和血液净化四大板块，形成了完整的产业链。
Weigao’s core businesses span four major sectors—medical consumables,medical equipment,orthopedics,and blood purification—forming a comprehensive industrial chain.
医疗耗材：威高的一次性输液器、注射器等产品以高性价比和严格质控著称，覆盖输液、注射、输血、护理等多个领域，深受基层医院青睐。
Medical Consumables:Weigao’s infusion sets,syringes,and other disposable products are known for their high cost-effectiveness and stringent quality control.They are widely used in infusion,injection,blood transfusion,and nursing,making them highly favored by grassroots hospitals.
医疗设备：自主研发的超声设备、监护仪和手术室设备已进入多家三甲医院，便携式彩超设备广泛应用于基层医疗和急救场景。
Medical Equipment:The company’s independently developed ultrasound systems,monitors,and operating-room devices have been adopted by many top-tier hospitals,while its portable ultrasound equipment is widely used in grassroots medical facilities and emergency care.
骨科医疗：骨科植入物如人工关节、脊柱固定系统在国内市场占有率领先，部分产品出口到欧美市场。
Orthopedics:Weigao’s orthopedic implants,including artificial joints and spinal fixation systems,hold leading market shares in China,with some products exported to Europe and the United States.
血液净化：血液透析设备和耗材打破了进口品牌垄断，旗下子公司生产的透析机和透析滤器已在全国数家透析中心投入使用，助力慢性肾病患者治疗普及化。
Blood Purification:Weigao’s dialysis machines and consumables have broken the monopoly of imported brands.Dialysis machines and filters produced by its subsidiaries are now in use at dialysis centers across the country,improving treatment accessibility for patients with chronic kidney disease.
三、创新与研发实力
III.Innovation and R&D Strength
威高深知技术创新是企业发展的命脉，设立了威海、上海等多个研发中心，聚集上千名专业人才，与114位两院院士建立合作关系，每年有三个品种打破国外垄断。
Weigao recognizes that technological innovation is the lifeblood of corporate development.It has established multiple R&D centers in Weihai,Shanghai,and other regions,gathering thousands of professionals and collaborating with114academicians from China’s national academies.Each year,at least three major product lines break foreign monopolies.
例如，自主研发的透析滤膜和骨科植入材料，打破了国外供应商的技术壁垒，降低了生产成本。
For example,its independently developed dialysis membranes and orthopedic implant materials have overcome technological barriers long dominated by foreign suppliers,significantly reducing production costs.
2024年，威高推出基于AI的骨科手术导航系统，可精准辅助医生进行复杂手术，提升成功率。
In2024,Weigao launched an AI-based orthopedic surgical navigation system,providing precise assistance for complex procedures and improving surgical success rates.
四、质量与社会责任
IV.Quality Commitment and Social Responsibility
威高视产品质量为患者和企业的生命，形成了“满足并努力超越顾客的最大需求”的质量方针和“10000-1=0”的经营理念，即对医药产品零容忍，确保每个产品都符合最高标准。
Weigao regards product quality as the lifeline of both the company and its patients.It upholds a quality philosophy of“meeting and striving to exceed customer expectations”and follows the principle of“10,000–1=0,”meaning zero tolerance for defects in medical products and uncompromising commitment to the highest standards.
此外，威高积极参与社会公益，如建立血液透析中心，降低患者治疗成本，为尿毒症患者带来希望。
In addition,Weigao actively engages in social welfare initiatives,such as establishing dialysis centers to reduce treatment costs and bring hope to patients suffering from uremia.
五、国际化战略
V.Internationalization Strategy
威高集团的国际化步伐稳健，产品出口到全球70多个国家和地区。通过设立海外分支机构，威高不断拓展国际市场，与国际先进企业合作，提升品牌影响力。
Weigao’s international expansion has been steady,with its products exported to more than70countries and regions.By establishing overseas branches,the company continues to broaden its global presence and strengthen partnerships with world-leading enterprises,enhancing its international brand influence.
未来，威高计划通过并购和合作，加速进入欧美高端市场。
In the future,Weigao plans to accelerate entry into high-end markets in Europe and the United States through mergers,acquisitions,and strategic collaborations.
威高集团从威海走向世界，用36年时间书写了中国医械行业的传奇。它不仅是企业的成功，更是中国医疗产业崛起的缩影。我们期待威高在国际舞台上继续发光发热，为全球医疗事业做出更大贡献。
From Weihai to the world,Weigao Group has written a remarkable chapter in China’s medical device industry over the past36years.It represents not only a corporate success story but also a vivid symbol of the rise of China’s medical sector.We look forward to seeing Weigao shine even brighter on the global stage and contribute further to global healthcare development.
